Trump to announce ‘TrumpRx’ site for discounted drugs and deal with Pfizer

President Trump is expected to announce a multi-pronged initiative to reduce U.S. drug costs, featuring a 'TrumpRx' direct-to-consumer website and the revival of a 'Most Favored Nation' (MFN) policy compelling drugmakers to align U.S. prices with the lowest international rates. This aggressive move, supported by an impending 100% tariff on imported brand-name pharmaceuticals lacking U.S. manufacturing, faces strong industry opposition from PhRMA, which warns of undermined leadership and potential legal challenges, with experts suggesting companies may opt to raise prices in other markets rather than significantly cut U.S. costs.

Analysis

The Trump administration is reportedly preparing to announce a multi-pronged initiative aimed at lowering US drug costs, creating significant regulatory and pricing uncertainty for the pharmaceutical sector. This effort centers on reviving the 'Most Favored Nation' (MFN) policy to align US prices with the lowest in comparable countries and promoting direct-to-consumer (DTC) channels, such as a proposed 'TrumpRx' website. The policy is backed by aggressive measures, including a looming 100% tariff on imported brand-name drugs from firms without US manufacturing and threats to revoke FDA approvals. While a specific deal with Pfizer (PFE) is mentioned, the wider industry is already responding to pressure, with Novo Nordisk (NVO) offering its blockbuster drug Ozempic via a DTC channel at a nearly 50% discount to its list price for cash-payers. However, significant skepticism exists regarding the President's legal authority to enforce MFN pricing, and industry actions suggest a strategic pivot rather than capitulation. Evidence from Eli Lilly (LLY), which raised Mounjaro's price in the UK to offset US cost pressures, indicates that firms may opt to increase ex-US prices to protect overall margins, a response that could undermine the policy's intended effect on US consumer costs.

Key Decisions for Investors

• Given the negative sentiment and heightened regulatory uncertainty, investors should increase scrutiny on pharmaceutical holdings with significant US revenue concentration, such as Pfizer, Novo Nordisk, and Eli Lilly.
• It is crucial to evaluate portfolio companies' manufacturing supply chains, as the threatened 100% tariff on specific imported drugs presents a direct margin risk for those reliant on non-US production for the American market.
• Monitor company-specific pricing strategies closely, as firms may mitigate US pricing pressure by increasing prices in international markets, a trend that could protect overall margins more than currently anticipated by the market.
• The accelerated push for direct-to-consumer sales channels represents a potential disruption to the PBM and insurer-based model, warranting a re-evaluation of long-term growth and margin assumptions for the sector.